Načítá se...
The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model
Background/Aim: Poly (ADP-ribose) polymerase (PARP) inhibition could enhance the efficacy of temozolomide and prolong survival in patients with glioblastoma. The aim of this study was to evaluate the combination of the PARP inhibitor olaparib with temozolomide in the treatment of glioblastoma. Mater...
Uloženo v:
| Vydáno v: | In Vivo |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
International Institute of Anticancer Research
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8286506/ https://ncbi.nlm.nih.gov/pubmed/34182476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.12470 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|